Current status of antibody therapy for breast cancer

被引：15
作者：
Masakazu Toi
Masahiro Takada
Hiroko Bando
Kazumi Toyama
Hiroyasu Yamashiro
Shinichiro Horiguchi
Shigehira Saji
机构：
[1] Tokyo Metropolitan Komagome Hospital,Department of Surgery
[2] Tokyo Metropolitan Cancer and Infectious Disease Center,Department of Pathology
[3] Komagome Hospital,undefined
来源：
Breast Cancer | 2004年 / 11卷 / 1期
关键词：
Her-2; Antibody; Trastuzumab; Breast cancer;
D O I：
10.1007/BF02967994
中图分类号：
学科分类号：
摘要：
Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.
引用
收藏
页码：10 / 14
页数：4
相关论文
共 187 条
  • [1] Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182
  • [2] Clark GM(1992)Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049-1056
  • [3] Wong SG(1994)c-erbB-2 expression and response to adjuvant therapy in women with node-negative early breast cancer N Engl J Med 330 1260-1266
  • [4] Levin WJ(1998)erbB-2, P53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1346-1360
  • [5] Ullrich A(1999)Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overex-pression metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639-2648
  • [6] McGuire WL(2002)Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719-726
  • [7] Gusterson B(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
  • [8] Gelber R(2002)Cardiac dysfunction in the Trastuzumab clinical trials experience J Clin Oncol 20 1215-1221
  • [9] Goldhirsch A(2001)Herceptin: the future in adjuvant breast cancer therapy Anti-Cancer Drug 12 S27-S33
  • [10] Price KN(1999)Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241-2251
12345678910